First, patients with early-stage HR+/HER2- breast cancer in the SOLTI-1805 TOT-HER3 trial received only one dose of HER3-DXd; therefore, it is unknown if the determinants of response identified in this study will be validated when patients receive more doses such as a full neoadjuvant course of treatment. This evidence concerns the gene ERBB2 and breast carcinoma.